Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma Marie ToukamJoseph P. BoniJens Wuerthner Original Article 04 November 2022 Pages: 1 - 12
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma Marie ToukamJens WuerthnerJoseph P. Boni Original Article 04 November 2022 Pages: 13 - 24
Incidence and risk factors of infusion reactions in patients with breast cancer administered trastuzumab plus pertuzumab-based regimen Yusuke TabuchiMasayuki TsujimotoKeisuke Shikata Original Article 19 November 2022 Pages: 25 - 31
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial Nikki de RouwRené J. BoosmanRob ter Heine Original Article 21 November 2022 Pages: 33 - 42
SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration Huawei XiaoXifeng YangShaoyan Huang Original Article 27 November 2022 Pages: 43 - 52
Comparison of the immunomodulatory potential of platinum-based anti-cancer drugs and anthracyclins on human monocyte-derived cells Viktória JeneiSára BuraiGábor Koncz Original Article Open access 30 November 2022 Pages: 53 - 66
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats J. WalladbegiM. DankisM. Winder Original Article Open access 01 December 2022 Pages: 67 - 75
Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia Miao LiXiao-Yan KongShu-Mei Wang Original Article 04 December 2022 Pages: 77 - 87
Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis Arunima JaiswalAruna JaiswalRobert Hromas Short Communication 08 November 2022 Pages: 89 - 95
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype Samantha MedwidTheodore J. WigleRichard B. Kim Short Communication 10 November 2022 Pages: 97 - 102